Back to search

Article

Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP)

2021-11-10

Abstract excerpt

While effective at preventing Zaire ebolavirus (EBOV) disease, cellular immunity to EBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing Ebola glycoprotein (rVSVΔG-EBOV-GP) vaccine remains poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ ClinicalTrials.gov NCT02788227 ] bef...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
07f0a227-8128-519e-83bc-84f54150b787
DOI
10.1101/2021.11.09.21266118
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP)DOI 10.1101/2021.11.09.21266118
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity
Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary ReportSemantic proximity
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 ProteinsSemantic proximity
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GPSemantic proximity
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsSemantic proximity
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemicSemantic proximity
Human Transcriptomic Response to the VSV-Vectored Ebola VaccineSemantic proximity
The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure DevelopmentSemantic proximity
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalSemantic proximity
Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical TrialSemantic proximity
Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year PersistenceSemantic proximity
Filoviridae: Insights into Immune Responses to EbolavirusSemantic proximity
Select a neighboring publication to make it the new centre.